Design and synthesis of potent C2-symmetric diol-based HIV-1 protease inhibitors: Effects of fluoro substitution

Journal of Medicinal Chemistry

Volumn 44, Issue 19, 2001, Pages 3083-3091

  Pyring, D ^a   Lindberg, J ^b   Rosenquist, A ^a   Zuccarello, G ^a   Kvarnstrom I ^a   Zhang, H ^c   Vrang, L ^c   Unge, T ^b   Classon, B ^c,d   Hallberg, A ^b   Samuelsson, B ^c,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MEDIVIR AB   (Sweden)

^d STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE; FLUOROBENZENE; N1,N6 BIS(HYDROXY 1 INDANYL) 2,5 BIS(2 FLUOROBENZYLOXY) 3,4 DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS(HYDROXY 1 INDANYL) 2,5 BIS(2,3 DIFLUOROBENZYLOXY) 3,4 DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS(HYDROXY 1 INDANYL) 2,5 BIS(2,5 DIFLUOROBENZYLOXY) 3,4 DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS(HYDROXY 1 INDANYL) 2,5 BIS(3 FLUOROBENZYLOXY) 3,4 DIHYDROXYHEXANEDIAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

AMIDES; CELL LINE; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ESCHERICHIA COLI; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDANS; MODELS, MOLECULAR; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035855914     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001134q     Document Type: Article

References (43)

1. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
2. Isolation of human T-cell leukemia virus in Acquired Immune Deficiency Syndrome (AIDS)
3. Isolation of a T-lymphocytic retrovirus from a patient at risk for Acquired Immune Deficiency Syndrome (AIDS)
4. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity
5. Active human immunodeficiency virus protease is required for viral infectivity
6. HIV protease inhibitors
7. Recent developments in HIV protease inhibitor therapy
8. HIV protease inhibitors
9. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
10. Structure-based inhibitors of HIV-1 protease
11. HIV protease: A novel chemotherapeutic target for AIDS
12. Rational design of peptide-based HIV proteinase inhibitors
13. ABT-538 is a potent inhibitor of Human Immunodeficiency Virus protease and has high oral bioavailability in humans
14. L-735,-524: An orally bioavailable Human Immunodeficiency Virus type 1 protease inhibitor
15. Iterative protein structure-based drug design and synthesis of HIV protease inhibitors
16. Design of VX-478, a potent inhibitor of HIV protease
17. ABT-378, a highly potent inhibitor of the Human Immunodeficiency Virus protease
18. Mutations in retroviral genes associated with drug resistance
19. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
20. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
21. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
22. Impact of the Central Hydroxyl Groups on the activity of symmetrical HIV-1 protease inhibitors derived from L-Mannaric acid
23. 2 symmetric template
24. 2-symmetric P1/P1′-Modified HIV-1 Protease inhibitors
25. 2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold
26. HIV-1 protease inhibitors based on acyclic carbohydrates
27. Structure-based design of symmetric inhibitors of HIV-1 protease
28. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease
29. Biosterism: A rational approach in drug design
30. A simple access to trichloroacetimidates
31. Benzylation of aldonolactones with benzyl trichloroacetimidate
32. A useful application of benzyl trichloroacetimidate for the benzylation of alcohols
33. Acid-catalysed benzylation and allylation by alkyl trichloroacetimidates
34. Benzyl trichloroacetimidate, a versatile reagent for acid-catalysed benzylation of hydroxy-groups
35. The nucleophilic reactivity of valine methylamide. A model of the N-terminal valine residues of hemoglobin
36. The synthesis of emetine and related compounds. Part VII. The utility of bifunctional catalysts in amine-ester interactions
37. 2+
38. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs
39. Improved methods for building protein models in electron density maps and the location of errors in these models
40. Molray: A Web-based Interface to POV-Ray for Production of High-quality Molecular-graphics Images from O Plot Files and Other Sources